|
|
|
10 Jun 2008 |
OSI Pharmaceuticals Presents Diabetes/Obesity Preclinical Compounds, PSN821 and PSN602, at Annual Meeting of the American Diabetes Association
|
|
10 Jun 2008 |
Incyte's Selective Oral Inhibitor of 11beta-HSD1 Demonstrates Improvements in Insulin Sensitivity and Lowers Cholesterol Levels in Type 2 Diabetics
|
|
10 Jun 2008 |
Elixir Pharmaceuticals Announces New Data at the 2008 American Diabetes Association Annual Meeting
|
|
10 Jun 2008 |
Hollis-Eden Pharmaceuticals Reports Additional Positive Data from Phase I/II Clinical Trial with TRIOLEX(TM) Supporting Anti-Inflammatory Approach to Treating Type 2 Diabetes
|
|
10 Jun 2008 |
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
|
|
09 Jun 2008 |
Phase 3 Results for alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
|
|
09 Jun 2008 |
ONGLYZA(TM) (saxagliptin) Demonstrated Significant Reductions in Key Measures of Glucose Control in Treatment Naive People with Type 2 Diabetes
|
|
09 Jun 2008 |
Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
|
|
09 Jun 2008 |
XOMA 052 Demonstrates Anti-Inflammatory Effects in Diabetes Animal Studies; Data Presented At ADA
|
|
09 Jun 2008 |
Orexigen(R) Therapeutics Announces That Contrave(R) May Reverse the Incidence of Metabolic Syndrome
|
|
09 Jun 2008 |
InteKrin Therapeutics Presents Phase 2a Data at American Diabetes Association Meeting for INT131, a non-TZD SPPARM
|
|
09 Jun 2008 |
Abbott's Phase III Sub-Group Analysis Shows Investigational TriLipix™ in Combination with CRESTOR® Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
|
|
09 Jun 2008 |
New Data Released at Major Diabetes Meeting on Initial Combination Therapy with JANUVIA(TM) (sitagliptin), Merck's Diabetes Medicine, and Metformin through Two Years of Treatment
|
|
09 Jun 2008 |
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
|
|
09 Jun 2008 |
New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
|
|
08 Jun 2008 |
Clinical study shows liraglutide provides statistically significantly better blood glucose control than exenatide
|
|
05 Jun 2008 |
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
|
|
05 Jun 2008 |
Generex Biotechnology Commences Patient Dosing For Pivotal Phase III Trial of Generex Oral-lyn
|
|
05 Jun 2008 |
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
|
|
05 Jun 2008 |
FDA broadens US indication for once-yearly Reclast® as only osteoporosis treatment approved for prevention of fractures after a hip fracture
|
|
05 Jun 2008 |
LCT Expands Diabetes Clinical Trial
|
|
02 Jun 2008 |
Phase III Study of Abbott's TriLipix™ in Combination With AstraZeneca's CRESTOR® Meets Primary Endpoints on LDL, Triglycerides and HDL
|
|
30 May 2008 |
AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
|
|
30 May 2008 |
Nuvo licenses topical pain product from Paladin
|
|
28 May 2008 |
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))
|
|
28 May 2008 |
LifeCycle Pharma A/S Announces Successful Completion of Pilot Studies on LCP-Feno and is Currently Preparing for Pivotal Studies LifeCycle Pharma Discontinues Service Agreements with Partners
|
|
26 May 2008 |
Voglibose (BASEN(R)) for the prevention of type 2 diabetes mellitus:A Randomized, Double-blind Trial in Japanese Subjects with Impaired Glucose Tolerance
|
|
23 May 2008 |
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
|
|
23 May 2008 |
Novo Nordisk files for regulatory approval of liraglutide in both the US and Europe
|
|
20 May 2008 |
Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
|
|
20 May 2008 |
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKUBioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
|
|
19 May 2008 |
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
|
|
15 May 2008 |
Ambrilia Reports Positive Final Phase III Results for its Octreotide Formulation C2L
|
|
14 May 2008 |
Co-Development and Co-Marketing Agreement Secured for the Activated Vitamin D Derivative, ED-71
|
|
13 May 2008 |
Piramal Life Sciences Initiates Phase I Trials with a New Molecule for Type II Diabetes in Europe
|
|
08 May 2008 |
Preliminary Results from Phase 2 Genzyme Study
|
|
07 May 2008 |
Orexigen(R) Therapeutics Announces Completion of Patient Enrollment in Phase III Clinical Program for Contrave(R)
|
|
07 May 2008 |
Osteologix IND for NB S101 for Osteoporosis Accepted by FDA
|
|
06 May 2008 |
Adenuric(R) (febuxostat) receives marketing authorisation in the European Union
|
|
06 May 2008 |
Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
|
|
06 May 2008 |
LifeCycle Pharma Announces Positive Data from LCP-AtorFen Phase II Clinical Program
|
|
05 May 2008 |
DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83
|
|
30 Apr 2008 |
OXiGENE Announces Preclinical Data Demonstrating that the Active Metabolite of ZYBRESTAT Improves Glucose Metabolism through Similar Mechanism as a Sirtuin Agonist
|
|
29 Apr 2008 |
FDA Approves Second Improvement to Unigene's Calcitonin Manufacturing Process
|
|
29 Apr 2008 |
Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)
|
|
28 Apr 2008 |
Metabasis Therapeutics Announces Positive Results in the Phase 2a Clinical Trial for MB07803, Its Product Candidate for the Treatment of Type 2 Diabetes
|
|
25 Apr 2008 |
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
|
|
24 Apr 2008 |
Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
|
|
23 Apr 2008 |
Metabasis Therapeutics Announces Extension of Its Collaboration with Merck & Co., Inc. to Develop AMPK Activators for Diabetes and Other Metabolic Diseases
|
|
22 Apr 2008 |
Dosing for RVX-208 Phase 1a Clinical Study Completed
|
| |
|
Results 151 - 200 of 1041 |
